Today: 11 June 2026
Browse Category

XETRA:BOSS 23 August 2025

2025’s Most Popular Men’s and Women’s Watches – Luxury Icons, Smartwatch Superstars, Fashion Favorites & Affordable Gems

2025’s Most Popular Men’s and Women’s Watches – Luxury Icons, Smartwatch Superstars, Fashion Favorites & Affordable Gems

Swiss watch exports hit a record CHF 26.7 billion in 2023. Rolex surpassed CHF 10 billion in annual revenue, selling about 1.24 million watches and capturing 30% of the market. The Big Four brands account for nearly 44% of Swiss watch market value. Smartwatches reached 455 million users worldwide, with Apple holding a 21% share.
23 August 2025
······

Stock Market Today

  • EMCOR Group (EME) Shares Show 33.7% Undervaluation Despite Strong Price Gains
    June 11, 2026, 10:55 AM EDT. EMCOR Group's (EME) stock closed at $776.72, up 21.6% year to date and 64.9% over the last year, but recent dips have raised valuation questions. Using a Discounted Cash Flow (DCF) analysis-a method that projects future cash flows discounted to present value-Simply Wall St estimates an intrinsic value of $1,171.22 per share. This suggests the stock is trading at a 33.7% discount, indicating undervaluation despite recent market pullbacks. The company benefits from strong exposure to U.S. construction and infrastructure projects, supporting its growth outlook. Investors should consider these factors alongside valuation metrics like price-to-earnings ratios when assessing EMCOR's attractiveness amidst sector dynamics.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop